Paul Yien Kwo (Paul Y Kwo, Paul Kwo)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 10

Top Venues

Alimentary pharmacology & therapeutics

Hepatology (Baltimore, Md.)

PloS one

Hepatology communications

Stanford University School of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Stanford University School of Medicine Nov 01 2016

United States

Professor of Medicine :: Medicine

Publications

Leslie Y Kam, Daniel Q Huang, Alfred F Tobias, Kitty Poon, Linda Henry, Paul Yien Kwo, Ramsey Cheung, Mindie H Nguyen
Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. Alimentary pharmacology & therapeutics 56 (11-12) (2022)
Saad Emhmed Ali, Philip Vutien, C Andrew Bonham, Charles Landis, Paul Yien Kwo, Carlos Esquivel, Mindie H Nguyen
Use and outcomes of hepatitis B virus-positive grafts in orthotopic liver transplantation in the United States from 1999 to 2021. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2022)
Omar Alshuwaykh, Tami Daugherty, Amanda Cheung, Aparna Goel, Renumathy Dhanasekaran, T Tara Ghaziani, Andrew A Li, Deepti Dronamraju, Radhika Kumari, Allison J Kwong, Mindie H Nguyen, W Ray Kim, Paul Yien Kwo
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy. Hepatology communications 6 (11) (2022)
Ashwani K Singal, Yong-Fang Kuo, K Rajender Reddy, Ramon A Bataller, Paul Yien Kwo
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Alimentary pharmacology & therapeutics 56 (10) (2022)
Calvin Qian Pan, Ira M Jacobson, Paul Martin, Paul Yien Kwo, Joseph Lim, Steven-Huy B Han, Ke-Qin Hu, Joseph Ahn, Myron J Tong
Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination. Hepatology (Baltimore, Md.) 75 (6) (2022)
Omar Alshuwaykh, Amanda Cheung, Aparna Goel, Allison Kwong, Renumathy Dhanasekaran, T Tara Ghaziani, Aijaz Ahmed, Tami Daugherty, Deepti Dronamraju, Radhika Kumari, Mindie Nguyen, W Ray Kim, Paul Yien Kwo
Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites. BMC gastroenterology 22 (1) (2022)
Branden D Tarlow, W Ray Kim, Ajitha Mannalithara, Paul Yien Kwo, C Andrew Bonham, Allison J Kwong
Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40. Hepatology (Baltimore, Md.) (2022)
Allison J Kwong, Paul Yien Kwo
Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Alimentary pharmacology & therapeutics 51 (7) (2020)
Paul Yien Kwo, Amy Puenpatom, Zuoyi Zhang, Siu L Hui, Andrea A Kelley, David Muschi
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PloS one 14 (8) (2019)
Katherine Wong, Katharine Ozeki, Allison Kwong, Bhavik N Patel, Paul Yien Kwo
The effects of a transjugular intrahepatic portosystemic shunt on the diagnosis of hepatocellular cancer. PloS one 13 (12) (2018)

Paul Yien Kwo.css-eqlu8i{font-size:small;padding-left:4px;} (Paul Y Kwo, Paul Kwo)

Publication Activity (10 Years)

Top Topics

Top Venues

Paul Yien Kwo (Paul Y Kwo, Paul Kwo)